Recombinant Antibody Services

Discover the power of our proprietary Lenti-mAb™ platform to obtain lighting-fast recombinant antibody-producing cells in as little as 8 weeks. Lenti-mAb represents a cutting-edge and efficient approach for the development of high-titer antibody-producing cell lines, which is crucial for the production of recombinant antibodies (rAbs) in therapeutic drug development. Unlike conventional methods, the Lenti-mAb platform elegantly consolidates expression of the heavy chain, light chain, and drug selection marker into a single lentiviral construct (Figure 1), allowing for the generation of an all-in-one high-titer lentivirus. This allows to increase gene integration and copy numbers to achieve high-titer rAb production. This innovative approach simplifies the process of establishing highly productive rAb stable cells, achieving high rAb gene copy-numbers without the need for repeated transfection and selection, allowing for rAb production in a wider range of cell types, and ensuring the scalable production of fully functional rAbs.

Discover the power of Lenti-mAb and
obtain high-producing clones in as little as 8 weeks

Every project manager understands that time is of the essence in the world of therapeutic drug development. For therapeutic antibodies, limitations associated with current methodologies mean that obtaining high-producing colonies and large quantities of purified antibodies can be a time consuming process. The Lenti-mAb platform streamlines time- and cost-efficiency by championing the generation of highly productive, stable (long-term) antibody-producing cells, thereby meeting the essential demands of recombinant antibody manufacturing (Figure 1). Our versatile platform accommodates antibodies of any isotype and specificity, including IgG1, IgG2, IgG3, IgG4, and kappa or lambda light chains, and opens doors for recombinant antibody production in a wider range of cell types, freeing the user from the constraints of fixed commercial cell line expression systems. Starting with the DNA sequence of antibodies (or simply VH and VL regions), our team of experts synthesize and clone the heavy chain (HC) and light chain (LC) genes into the Lenti-mAb lentiviral expression system (Figure 2), followed by the generation of high-titer lentivirus, which can be supplied within 4 weeks. Then, depending on the level of service required, we will perform transduction and selection of the target cells, screen for high-producing colonies, and express and purify the recombinant antibodies. Not only does our cost-effective approach ensure competitive pricing, but our commitment to efficiency means we can deliver custom recombinant antibodies to you within an approximate twelve-week timeframe, or high-producing cell lines in as little as 8 weeks.


Figure 2. Schematic components of Lenti-mAb vector. 

Service Guide

Option 1: High-Titer Lentivirus

Our recombinant antibody service starts with the customer providing the DNA or amino acid sequences of the HC and LC Fv regions. Option 1 includes the synthesis and cloning of the DNA fragments into our Lenti-mAb vector, expression validation for the cloned plasmid, and the preparation of high-titer VSV-G pseudotyped lentivirus, which can be used to transduce a wide range of mammalian cells. Customers can expect to receive the lentivirus in approximately 4 weeks.

Option 2: High-Producing Cells

Option 2 allows the customer to obtain high-producing cells generated by us using the Lenti-mAb system. After DNA synthesis, cloning, and the production of high-titer lentivirus, we transduce and select the drug-resistant target cells. Then, we pick and screen single colonies for high-production of recombinant antibodies. After providing the DNA sequence, customers can anticipate receiving high rAb-producing cells in approximately 8 weeks.

Option 3: High-Quality Purified Antibodies

In this extended service, we expand and bank the high-producing cells, followed by the expression and purification of recombinant antibody. Customers can receive their custom recombinant antibodies within an approximate 12-week timeframe from the time we receive the DNA sequence.

Whether you require high-titer lentivirus, high-producing cells, or a complete package for high-quality recombinant antibody production, our streamlined processes and dedication to efficiency ensure you to receive top-notch products and services tailored to your requirements.

Why Choose Us

Conventional approaches for recombinant antibody production are more time-consuming than the streamlined approach provided by the Lenti-mAb platform. Extensive selection and screening efforts associated with plasmid-based transfection creates a bottleneck in recombinant antibody development that can be costly and unstable, especially when large quantities of recombinant antibodies are needed.

By utilizing an all-in-one lentiviral system, the Lenti-mAb platform offers several key benefits:

  • Stable and Long-term Antibody Production: Lentiviral integration into the host cell’s genome is a superior method for the stable expression of the recombinant gene over extended periods. This results in sustained antibody production, making lentivirus-infected cells an ideal choice for long-term antibody production and therapeutic applications.

  • High Transduction Efficiency: Our proprietary lentiviral vector has been optimized to demonstrate exceptional transduction efficiency, ensuring that a significant portion of the target cells integrate the antibody genes into their genome. This translates to a high number of antibody-producing colonies that can be quickly picked up to screen for high production capacity following drug selection with either puromycin or blasticidin. By addressing the key bottleneck in recombinant antibody development caused by extensive selection and screening, the Lenti-mAb platform streamlines the process of identifying high-producing colonies and reduces developmental timelines.

  • Scalability: Cells that have been lentivirally transduced using Lenti-mAb can be expanded in culture, enabling the scalable production of antibodies. This feature is particularly valuable for generating large quantities of antibodies.

  • Versatility: The Lenti-mAb vector can accommodate various antibody isotypes (IgG1, IgG2, IgG3, IgG4, and kappa or lambda light chains) and species based on the antibody sequence information you provide. This versatility empowers the end user to generate antibodies with diverse characteristics, suitable for a wide range of applications in clinical drug development and academic research. In addition, the inherent advantages of the VSV-G pseudotyped lentivirus provides freedom to infect a wide range of mammalian cell types, opening doors for exploration of recombinant antibody expression in different species, tissues, or cells.

  • One-step Assembly: Core to the efficiency of the Lenti-mAb system is the consolidation of heavy chain, light chain, and drug selection marker (puromycin or blasticidin) into a single, all-in-one lentiviral construct. The resulting lentiviral particles are thus capable of directing genomic integration of the entire antibody expression system in a single transduction. This feature greatly simplifies the establishment of highly productive and stable recombinant antibody expressing cells, enabling efficient and scalable production of fully functional recombinant antibodies.

  • Cost-effective System: The unprecedented efficiency and simplicity of our system allows us to offer an affordable pricing structure to our customers.

At LipExoGen, we are committed to providing you with an efficient, versatile, and cost-effective solution for all your antibody expression needs. Choose us for a streamlined and reliable process that ensures the production of high-quality antibodies tailored to your specific requirements.

Case Study

We have consistently offered our clients a specialized service for producing recombinant antibodies within their specified cells. The case study below exemplifies our process, focusing on a customer who was interested in rapidly obtaining purified recombinant anti-CD33 antibodies utilizing their proprietary DNA sequence.


Antibody-Producing Cell Screening:

The primary objective at this stage is to isolate high-capacity antibody-producing cells. After infection with high-titer lentivirus produced using the customer’s DNA sequence, the transduced cells underwent puromycin selection. Colonies of infected cells were then chosen specifically to identify those with high antibody-producing capacities. We use the culture medium from each cell colony and screen it with Western-blot (Figure 3A). Typically, after screening 25 to 30 colonies, we can establish a stable, high-producing cell line.

Purification of rAb and Gel Image Analysis:

Once we’ve identified high producing cells, the next step is the purification of the antibody. The success of this purification is then verified through a gel image stained with Coomassie blue, emphasizing the purified rAb after its treatment with DTT (Dithiothreitol) (Figure 3B). 

Functional Validation:

In this case, we produced a recombinant anti-human CD33 antibody. To assess its functionality, the antibody was fluorescently labeled and used to stain human AML cells provided by the client. The results confirm the functionality of the recombinant anti-CD33 antibody, given its robust binding affinity to the cells, which is known to exhibit surface CD33 expression based on separate staining with commercially available fluorescent anti-CD33 antibodies.

Figure 3. Snapshots of the validation procedure for recombinant antibody development using the Lenti-mAb system        A. Antibody-producing cell screening. Cell culture medium from individual colonies of the lentivirus-transduced and puromycin-resistant HEK cells are analyzed by Western blot to identify those with high expression of the recombinant antibodies. B. Reducing SDS-PAGE with Coomassie blue stain is performed to verify successful purification of the expressed recombinant antibody. C. The functionality of the purified recombinant antibody was assessed by fluorescently labeling with Alexa Fluor 488, followed by immunofluorescence staining the human CD33 expressing AML cells provided by the client. D. Further functional validation was demonstratred using the fluorescently-labeled antibody using flow cytometry with the clients’ human AML cells.

Get Started...


Call: 410-231-3496

Need Help Shopping Online?

Our customer support team is ready to help.